Clinical trials: Neoadjuvant Therapies
Rectal Cancer Patients, Total Neoadjuvant Therapy
Nodal Downstaging Versus Primary Tumor Regression as Predictors of Survival After Total Neoadjuvant Therapy for Rectal Cancer: A Retrospective Study
To evaluate the prognostic impact of post-TNT pathological nodal status (ypN) on LRFS, DMFS, and OS, and compare it with that of primary tumor response
- Trial name
- NCT07557316
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
NSCLC, Neoadjuvant Therapy
Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer
China with high incidence of non-small cell lung cancer. In the past few decades, surgery, radiotherapy, chemotherapy and other treatments were continuously improved, however, the mortality of lung cancer patients was not…
- Trial name
- NCT05882513
- Testing
- Serplulimab and neoadjuvant therapy, surgical resection of lung cancer, Tumour will be Collected from participant. Fate of sample is Destruction after use
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Neoadjuvant Therapy
Digital Mind-Body Therapy for Neoadjuvant Breast Cancer
This study is a single-center, randomized controlled, prospective trial investigating the application of Digital Mind-Body Therapy based on digital music and biofeedback (DMBT) during neoadjuvant treatment in patients with…
- Trial name
- NCT07541664
- Testing
- DMBT
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Fudan University
Locally Advanced Rectal Cancer, Neoadjuvant Therapy
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
TORCH-iTNT is a prospective, multicentre, randomized phase II trial. 198 LARC (T3-4/N+M0, distance from anal verge ≤12cm) patients will be treated with total neoadjuvant therapy (TNT) and assigned to Group A and Group B (1:1).
- Trial name
- TORCH-iTNT (NCT06281405)
- Testing
- PD-1 inhibitor, Capecitabine, Short-course radiotherapy
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Fudan University
Non-Small Cell Lung Cancer, PET/CT
FAP-targeted PET/NIR in Lung Malignant Tumors
Single center, prospective, diagnostic study. Patients with stage II-IIIB resectable NSCLC diagnosed by pathology were included.
- Conditions
- Non-Small Cell Lung Cancer, PET/CT, Neoadjuvant Therapy
- Trial name
- NCT07498933
- Testing
- PET/CT scans
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University People's Hospital
Breast Cancer, Neoadjuvant Therapy
Circulating microRNAs and Response to Neoadjuvant Chemotherapy in Breast Cancer
This prospective observational study aims to investigate subtype-specific circulating microRNAs (miRNAs) and their association with response to neoadjuvant chemotherapy (NAC) in patients with breast cancer.
- Conditions
- Breast Cancer, Neoadjuvant Therapy, Pathological Response, Invasive Breast Carcinoma
- Trial name
- miRNA-NAC (NCT07289282)
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Atlas University
Neoadjuvant Therapy, Urothelial Carcinoma Ureter
Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial
This clinical trial aims to compare the effectiveness and safety of two treatment options for patients with high-risk upper tract urothelial carcinoma (UTUC).
- Conditions
- Neoadjuvant Therapy, Urothelial Carcinoma Ureter, Upper Urinary Tract Urothelial Carcinoma
- Trial name
- NCT07492225
- Testing
- Neoadjuvant Gemcitabine + Cisplatin Chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Changhai Hospital
Resectable NSCLC, KRAS G12C Mutation
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
This is an exploratory study evaluating the efficacy and safety of neoadjuvant therapy with fulzerasib sequentially combined with sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small cell lung…
- Conditions
- Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC, Neoadjuvant Therapy
- Trial name
- K-NADIR (NCT07492342)
- Testing
- fulzerasib
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Jianxing He
NSCLC, Neoadjuvant Therapy
Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）
This observational study aims to construct and validate the performance of a multimodal predictive model in forecasting the outcomes of neoadjuvant therapy in patients with NSCLC.
- Trial name
- NCT07388771
- Where
- 2 sites in China
- Volunteers
- 500 people
- Sponsor
- Qian Chu
Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer
To evaluate the efficacy and safety of Serplulimab in combination with Trastuzumab Restuzumab for the neoadjuvant treatment of triple-negative breast cancer, aiming to provide evidence for optimizing the strategy of combining…
- Trial name
- NCT07466303
- Testing
- Serplulimab, SHR-A1811
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Xijing Hospital
Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
This prospective, single-center, randomized controlled trial aims to assessing the efficacy and safety of neoadjuvant chemoradiation plus Tislelizumab (PD-1 inhibitor) with or without Probio-M9 and subsequent TME surgery, by…
- Conditions
- Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy, Probio-M9
- Trial name
- NCRIT-PM9 (NCT07458529)
- Testing
- CRT+PD-1 inhibitor+Probio-M9
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Seventh Medical Center of PLA General Hospital
Breast Cancer, HER2 + Breast Cancer
Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib
This is a pragmatic phase 2 study to determine the proportion of patients with ER+ (≥10%)/HER2- EBC in whom neoadjuvant chemotherapy can be replaced by NET plus abemaciclib based on the results of the ODX RS obtained in the…
- Conditions
- Breast Cancer, HER2 + Breast Cancer, HR Positive, Neoadjuvant Therapy
- Trial name
- VIOLET (NCT07428018)
- Testing
- Abemaciclib
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Lung Neoplasms, Neoadjuvant Therapy
To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
This project aims to innovatively integrate multi-omics data, including plasma metabolomics, radiomics, and cfDNA multi-level information, combined with survival data (e.g., RFS), to establish a novel multidimensional approach…
- Conditions
- Lung Neoplasms, Neoadjuvant Therapy, Immunotherapy, Minimal Residual Disease
- Trial name
- NCT07291921
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Breast Cancer, Neoadjuvant Chemotherapy
The Effect of Neoadjuvant Chemotherapy on Physical Functions
The aim of this observational study was to investigate the effect of neoadjuvant chemotherapy on physical functioning in individuals with breast cancer.
- Conditions
- Breast Cancer, Neoadjuvant Chemotherapy, Neoadjuvant Therapy
- Trial name
- NCT06986005
- Testing
- No intervention will be performed as part of this study. However, regardless of the study, all participants will receive neoadjuvant chemotherapy.
- Where
- Turkey (Türkiye)
- Volunteers
- 67 people
- Sponsor
- ATİYE KAŞ ÖZDEMİR
Colorectal Carcinoma (CRC), Complications
Perioperative Outcomes After Neoadjuvant Therapy in Colorectal Cancer
This prospective study investigates the effects of neoadjuvant therapy on endothelial function, microvascular tissue density, and tissue fibrosis in patients with colorectal cancer and their association with perioperative…
- Conditions
- Colorectal Carcinoma (CRC), Complications, Neoadjuvant Therapy, Endothelial Dysfunction
- Trial name
- Neocolon (NCT07422974)
- Testing
- Skin and subcutaneous tissue sampling for histopathological analysis, Blood sampling for laboratory analyses before and after surgery
- Where
- Croatia
- Volunteers
- 68 people
- Sponsor
- Osijek University Hospital
Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Through the combination of aparolitovorelli monoclonal antibody and lenvatinib neoadjuvant therapy, partial nephrectomy can be successfully and safely performed in patients with localized renal cell carcinoma (T1N0M0 or T2N0M0)…
- Conditions
- Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy
- Trial name
- NCT07389629
- Testing
- QL1706 Combined With Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC)
Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC
Through the neoadjuvant treatment with a combination of Pucotenlimab and Vorolanib, it enabled the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who had indications for…
- Conditions
- Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC), Neoadjuvant Therapy
- Trial name
- NCT07386158
- Testing
- Pucotenlimab combination with Vorolanib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Neoadjuvant Therapy
No Axillary Surgical Treatment in Clinically Lymph Node Negative Patients on Ultrasonography After Neoadjuvant Chemotherapy
NEO-NAUTILUS is a prospective, multicenter, randomized phase III clinical trial to evaluate whether omitting axillary lymph node surgery (ALND or SLNB) in clinically lymph node-negative breast cancer patients after neoadjuvant…
- Conditions
- Breast Cancer, Neoadjuvant Therapy, Sentinel Lymph Node Biopsy
- Trial name
- Neo-NAUTILUS (NCT06704945)
- Testing
- No axillary surgery, Axillary surgery
- Where
- South Korea
- Volunteers
- 464 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma, Neoadjuvant Therapy
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
Surgical resection is the preferred therapeutic modality for patients with resectable hepatocellular carcinoma (HCC). However, the recurrence rate of HCC remains up to 70%.
- Conditions
- Hepatocellular Carcinoma, Neoadjuvant Therapy, Sintilimab, Bevacizimab
- Trial name
- NCT07324824
- Testing
- sintilimab combined with bevacizumab biosimilar
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-sen University
Adult Patients With Locally Advanced Rectal Cancer Indicated to Neoadjuvant Therapy and Surgery
Postoperative Complications After Neoadjuvant Chemoradiotherapy or Short-course Radiotherapy and Total Neoadjuvant Treatment: a Multicentric Retrospective Cohort Study
The primary objective of the study is to compare the rate of postoperative complications between rectal cancer patients undergoing standard neoadjuvant chemoradiotherapy or short- course radiotherapy and patients receiving TNT.
- Trial name
- POCAT (NCT07346248)
- Testing
- Chemoradiotherapy
- Where
- Italy
- Volunteers
- 266 people
- Sponsor
- Istituto Clinico Humanitas